आईएसएसएन: 2332-0877

संक्रामक रोग और थेरेपी जर्नल

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • सूचकांक कॉपरनिकस
  • गूगल ज्ञानी
  • जे गेट खोलो
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • ईबीएससीओ एज़
  • ओसीएलसी- वर्ल्डकैट
  • पबलोन्स
  • यूरो पब
  • आईसीएमजेई
इस पृष्ठ को साझा करें

अमूर्त

Medicinal Plants, an Important Reserve of Antimycobacterial and Antitubercular Drugs: An Update

María Adelina Jiménez-Arellanes, Gabriel Gutiérrez-Rebolledo, Susana Rojas-Tomé and Mariana Meckes- Fischer

Background: Tuberculosis is a global and serious Public Health problem due to the increase of multidrugresistant and extensively drug-resistant cases; as a result, diverse research groups worldwide are focusing their efforts on finding novel antituberculous agents that can provide greater effectiveness, less toxicity and having a specific mechanism of action, possibly being coadjuvants in the treatments currently prescribed.

Methods: The present review covers the literature published concerning secondary metabolites of those Mexican medicinal plants and secondary metabolites isolated from them showing in vitro antimycobacterial activity with MIC <50 μg/mL against sensitive and MDR M. tuberculosis strains as well as against NTM strains. The review also includes a special section for those natural compounds or plant extracts with antitubercular activity evaluated an in vivo experimental tuberculosis model.

Results: Some pure compounds with MIC<25 μg/mL are: 2-oxo-14-(3´,4´-methylenedioxyphenyl) tetradecane, 2- oxo-16-(3´,4´-methylenedioxyphenyl)hexadecane, 5,6-dehydro-7,8-dihydro methysticin, cepharanone B and piperolactam A (from Piper sanctum), suberosin (from Arracacia tolucensis) and leubethanol (from Leucophyllum frutescens). In addition, (-)-licarin A (from Aristolochia taliscana) was active against M. tuberculosis H37Rv, 12 MDR M. tuberculosis clinical isolates and four non-tuberculous mycobacteria. On the other hand, the antitubercular activity of (-)-licarin A, ursolic acid and oleanolic acid has been determined in a TB murine experimental in vivo model; (-)-licarin A reduces the bacterial lung load and the percentage of pneumonia in animals infected with M. tuberculosis H37Rv and MDR M. tuberculosis. The mixture of ursolic and oleanolic acids showed a significant reduction of bacterial loads and pneumonia in animals infected with M. tuberculosis H37Rv and MDR M. tuberculosis.

Conclusion: Since (-)-licarin A, ursolic acid and oleanolic acid have been evaluated as antitubercular compounds, these metabolites are candidates proposed feasible to be proposed for development of antituberculosis drugs.